All In Biotech

Drug Trial Radar · NCT00004339

Study of Tetrathiomolybdate in Patients With Wilson Disease

Last checked: Nov 20, 2026Latest source record: May 9, 2006 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

90

Actual

Start

Jan 1994

Primary completion

Not stated

Sponsor

Sponsor type
NIH
Collaborators
University of Michigan
First posted
Oct 19, 1999

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Masking
Double
Primary purpose
Treatment
Who can join
All sexes, from 0 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

OBJECTIVES: Evaluate the safety and efficacy of ammonium tetrathiomolybdate alone and compared with trientine therapy as initial treatment in patients with Wilson disease presenting neurologically.

Conditions

  • Wilson Disease

Interventions

  • tetrathiomolybdateDrug

  • trientineDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

No primary outcomes listed.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Michigan

    Ann Arbor, Michigan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.